![Sample our Bioscience journals, sign in here to start your access, Latest two full volumes FREE to you for 14 days]({"type":"image" , "src" : "/sda/5925/TOC-Subject-Sample-2021-Bioscience.jpg"})
Abstract
Two stage switching between testing for superiority (SUP) and noninferiority (NI) has been an important statistical issue in the design and analysis of the active-controlled clinical trials. Tsong and Zhang (Citation2005) has shown that the Type I error rates do not change when switching between SUP and NI with the traditional generalized historical control (GHC) approach, however, they may change when switching with the cross-trial comparison (X-trial) approach. Tsong and Zhang (Citation2005) further proposed a simultaneous test for both hypotheses to avoid the problem. The procedure was based on Fieller's confidence interval proposed by Hauschke et al. (Citation1999). Since with the X-trial approach, using the simultaneous test, superiority is tested using all four treatment arms (current test and active control arms, active control and placebo arms in historical trials), the Type I error rate and power are expected to be somewhat different from the conventional superiority test (using the current test and active control arms only). Through a simulation study, we demonstrate that the Type I error rate and power between simultaneous test and the conventional superiority test are compatible. We also examine the impact of the assumption of equal variances of the current trial and the historical trial.
ACKNOWLEDGMENT
This research project is completed with funding from CDER regulatory Research Science Research fund RSR07-01.
Notes
∗The simulation error of Type I error rate equals approximately √[(0.025 × 0.975)/10,000] = 0.00156.
∗The simulation error of Type I error rate equals approximately √[(0.025 × 0.975)/10,000] = 0.00156.
∗This paper does not represent the official position of U.S. Food and Drug Administration.